Nontraditional Uses of Continuous Glucose Monitoring

Published:September 09, 2022DOI:


      • Continuous glucose monitoring (CGM) can help identify and manage dysglycemia.
      • Patients who do not meet traditional criteria for CGM use may benefit.
      • Real-time glucose data can motivate lifestyle and dietary changes in some users.
      • CGM is a useful tool in the primary care setting for the assessment and treatment of patients with prediabetes and those with dysglycemia but no known diabetes.


      For patients with diabetes, continuous glucose monitoring (CGM) data viewed in real time alert users to existing or impending abnormal glucose values and guide insulin delivery. Data reviewed retrospectively can guide therapy adjustments. In populations without overt diabetes, CGM data may provide insights into glucose fluctuations resulting from diet and lifestyle. We present 5 cases of nontraditional CGM use at a primary care clinic. Patients wore unblinded CGMs to monitor glucose in real time and reviewed their data with a nurse practitioner. We discuss the potential impact of CGM in nontraditional groups as a clinical assessment and patient feedback tool.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The Journal for Nurse Practitioners
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • American Diabetes Association Professional Practice Committee
        7. Diabetes technology: Standards of Medical Care in Diabetes—2022.
        Diabetes Care. 2022; 45: S97-S112
        • Beck R.W.
        • Riddlesworth T.
        • Ruedy K.
        • Ahmann A.
        • Bergenstal R.
        • Haller S.
        • et al.
        Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial.
        JAMA. 2017; 317: 371-378
        • Lind M.
        • Polonsky W.
        • Hirsch I.B.
        • Heise T.
        • Bolinder J.
        • Dahlqvist S.
        • et al.
        Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial.
        JAMA. 2017; 317: 379-387
        • Martens T.
        • Beck R.W.
        • Bailey R.
        • Ruedy K.J.
        • Calhoun P.
        • Peters A.L.
        • et al.
        Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial.
        JAMA. 2021; 325: 2262-2272
        • Deshmukh H.
        • Wilmot E.G.
        • Gregory R.
        • Barnes D.
        • Narendran P.
        • Saunders S.
        • et al.
        Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) Nationwide Audit.
        Diabetes Care. 2020; 43: 2153-2160
        • Heinemann L.
        • Freckmann G.
        • Ehrmann D.
        • Faber-Heinemannn G.
        • Guerra S.
        • Waldenmaier D.
        • et al.
        Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial.
        Lancet. 2018; 391: 1367-1377
        • Beck S.E.
        • Kelly C.
        • Price D.A.
        • COACH Study Group
        Non-adjunctive continuous glucose monitoring for control of hypoglycaemia (COACH): results of a post-approval observational study.
        Diabet Med. 2022; 39e14739
        • Nathanson D.
        • Svensson A.M.
        • Miftaraj M.
        • Franzén S.
        • Bolinder J.
        • Eeg-Olofsson K.
        Effect of flash glucose monitoring in adults with type 1 diabetes: a nationwide, longitudinal observational study of 14,372 flash users compared with 7691 glucose sensor naive controls.
        Diabetologia. 2021; 64: 1595-1603
        • Polonsky W.H.
        • Hessler D.
        • Ruedy K.J.
        • Beck R.W.
        • DIAMOND Study Group
        The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial.
        Diabetes Care. 2017; 40: 736-741
        • Charleer S.
        • De Block C.
        • Van Huffel L.
        • Broos B.
        • Fieuws S.
        • Nobels F.
        • et al.
        Quality of life and glucose control after 1 year of nationwide reimbursement of intermittently scanned continuous glucose monitoring in adults living with type 1 diabetes (FUTURE): a prospective observational real-world cohort study.
        Diabetes Care. 2020; 43: 389-397
        • Hirsch I.B.
        • Miller E.
        Integrating continuous glucose monitoring into clinical practices and patients’ lives.
        Diabetes Technol Ther. 2021; 23: S72-S80
        • Steck A.K.
        • Dong F.
        • Geno Rasmussen C.
        • Bautista K.
        • Sepulveda F.
        • Baxter J.
        • et al.
        CGM metrics predict imminent progression to type 1 diabetes: Autoimmunity Screening for Kids (ASK) Study.
        Diabetes Care. 2022; 45: 365-371
        • Hoss U.
        • Budiman E.S.
        • Liu H.
        • Christiansen M.P.
        Feasibility of using a factory-calibrated CGM system to diagnose type 2 diabetes.
        J Diabetes Sci Technol. 2014; 8: 89-94
        • Shah V.N.
        • DuBose S.N.
        • Li Z.
        • Beck R.W.
        • Peters A.L.
        • Weinstock R.
        • et al.
        Continuous glucose monitoring profiles in healthy nondiabetic participants: a multicenter prospective study.
        J Clin Endocrinol Metab. 2019; 104: 4356-4364
        • Nguyen Q.
        • Pandya S.
        • Chin K.
        • Parkin C.G.
        Use of continuous glucose monitoring in detecting reactive hypoglycemia in individuals without diabetes.
        J Diabetes Sci Technol. 2018; 12: 1244-1245
        • Jaklevic M.C.
        Start-ups tout continuous glucose monitoring for people without diabetes.
        JAMA. 2021; 325: 2140-2142
        • Vitale V.
        • Berg L.C.
        • Larsen B.B.
        • Hannesdottir A.
        • Dybdahl Thomsen P.
        • Hyldahl Laursen S.
        • et al.
        Blood glucose and subcutaneous continuous glucose monitoring in critically ill horses: a pilot study.
        PLoS One. 2021; 16: e0247561
        • Ehrhardt N.
        • Al Zaghal E.
        Continuous glucose monitoring as a behavior modification tool.
        Clin Diabetes. 2020; 38: 126-131
        • Yoo H.J.
        • An H.G.
        • Park S.Y.
        • Ryu O.H.
        • Kim H.Y.
        • Seo J.A.
        • et al.
        Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes.
        Diabetes Res Clin Pract. 2008; 82: 73-79
        • Bergenstal R.M.
        • Layne J.E.
        • Zisser H.
        • Gabbay R.A.
        • Barleen N.A.
        • Armento Lee A.
        • et al.
        Remote application and use of real-time continuous glucose monitoring by adults with type 2 diabetes in a virtual diabetes clinic.
        Diabetes Technol Ther. 2021; 23: 128-132
        • Martens T.W.
        • Simonson G.D.
        • Carlson A.L.
        • Bergenstal R.M.
        Primary care and diabetes technologies and treatments.
        Diabetes Technol Ther. 2021; 23: S143-S158
        • Shrivastav M.
        • Gibson Jr., W.
        • Shrivastav R.
        • Elzea K.
        • Khambatta C.
        • Sonawane R.
        • et al.
        Type 2 diabetes management in primary care: the role of retrospective, professional continuous glucose monitoring.
        Diabetes Spectr. 2018; 31: 279-287
        • Johnson M.L.
        • Martens T.W.
        • Criego A.B.
        • Carlson A.L.
        • Simonson G.D.
        • Bergenstal R.M.
        Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice.
        Diabetes Technol Ther. 2019; 21: S217-S225
        • Battelino T.
        • Danne T.
        • Bergenstal R.M.
        • Amiel S.A.
        • Beck R.
        • Biester T.
        • et al.
        Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range.
        Diabetes Care. 2019; 42: 1593-1603
        • Ehrhardt N.
        • Al Zaghal E.
        Behavior modification in prediabetes and diabetes: potential use of real-time continuous glucose monitoring.
        J Diabetes Sci Technol. 2019; 13: 271-275
        • Lupoli R.
        • Lembo E.
        • Rainone C.
        • Schiavo L.
        • Iannelli A.
        • Di Minno M.N.D.
        • et al.
        Rate of post-bariatric hypoglycemia using continuous glucose monitoring: a meta-analysis of literature studies.
        Nutr Metab Cardiovasc Dis. 2022; 32: 32-39
        • Vigersky R.A.
        Going beyond HbA1c to understand the benefits of advanced diabetes therapies.
        J Diabetes. 2019; 11: 23-31
        • Beck R.W.
        • Connor C.G.
        • Mullen D.M.
        • Wesley D.M.
        • Bergenstal R.M.
        The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading.
        Diabetes Care. 2017; 40: 994-999
        • Schumacher C.
        A misdiagnosis of type 2 diabetes mellitus: using continuous glucose monitoring to improve patient-centered care.
        J Am Pharm Assoc. 2022; 62: 281-284
        • Bellido V.
        • Pinés-Corrales P.J.
        • Villar-Taibo R.
        • Ampudia-Blasco F.J.
        Time-in-range for monitoring glucose control: is it time for a change?.
        Diabetes Res Clin Pract. 2021; 177108917
        • Beck R.W.
        • Bergenstal R.M.
        Beyond A1C-standardization of continuous glucose monitoring reporting: why it is needed and how it continues to evolve.
        Diabetes Spectr. 2021; 34: 102-108
        • Cox D.J.
        • Banton T.
        • Moncrief M.
        • Conaway M.
        • Diamond A.
        • McCall A.L.
        Minimizing glucose excursions (GEM) with continuous glucose monitoring in type 2 diabetes: a randomized clinical trial.
        J Endocr Soc. 2020; 4: 1-7
        • Taylor P.J.
        • Thompson C.H.
        • Luscombe-Marsh N.D.
        • Wycherley T.P.
        • Wittert G.
        • Brinkworth G.D.
        Efficacy of real-time continuous glucose monitoring to improve effects of a prescriptive lifestyle intervention in type 2 diabetes: a pilot study.
        Diabetes Ther. 2019; 10: 509-522
        • Kruger D.F.
        • Anderson J.E.
        Continuous glucose monitoring (CGM) is a tool, not a reward: unjustified insurance coverage criteria limit access to CGM.
        Diabetes Technol Ther. 2021; 23: S45-S55
        • Galindo R.J.
        • Parkin C.G.
        • Aleppo G.
        • Carlson A.L.
        • Kruger D.F.
        • Levy C.J.
        • et al.
        What’s wrong with this picture? A critical review of current Centers for Medicare & Medicaid Services coverage criteria for continuous glucose monitoring.
        Diabetes Technol Ther. 2021; 23: 652-660
        • Edelman S.V.
        • Cavaiola T.S.
        • Boeder S.
        • Pettus J.
        Utilizing continuous glucose monitoring in primary care practice: what the numbers mean.
        Prim Care Diabetes. 2021; 15: 199-207


      Paul Kapsar, MSN, FNP-BC, SilverArc APN, Las Vegas, NV, and can be contacted at [email protected]


      Christy Chao, PhD, Dexcom, Inc., San Diego, CA.


      Tomas Walker, DNP, CDCES, Dexcom, Inc., San Diego, CA.